98%
921
2 minutes
20
Using siRNAs to genetically manipulate immune cells is important to both basic immunological studies and therapeutic applications. However, siRNA delivery is challenging because primary immune cells are often sensitive to the delivery materials and generate immune responses. We have recently developed an amphiphilic dendrimer that is able to deliver siRNA to a variety of cells, including primary immune cells. We provide here a protocol for the synthesis of this dendrimer, as well as siRNA delivery to immune cells such as primary T and B cells, natural killer cells, macrophages, and primary microglia. The dendrimer synthesis entails straightforward click coupling followed by an amidation reaction, and the siRNA delivery protocol requires simple mixing of the siRNA and dendrimer in buffer, with subsequent application to the primary immune cells to achieve effective and functional siRNA delivery. This dendrimer-mediated siRNA delivery largely outperforms the standard electroporation technique, opening a new avenue for functional and therapeutic studies of the immune system. The whole protocol encompasses the dendrimer synthesis, which takes 10 days; the primary immune cell preparation, which takes 3-10 d, depending on the tissue source and cell type; the dendrimer-mediated siRNA delivery; and subsequent functional assays, which take an additional 3-6 d.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830918 | PMC |
http://dx.doi.org/10.1038/s41596-020-00418-9 | DOI Listing |
Brain
September 2025
State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Guangdong Provincial Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Rege
Abnormal accumulation of TAR DNA-binding protein-43 (TDP-43) is a hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Small interfering RNAs (siRNAs) targeting TDP-43 offer potential therapeutic strategies for these diseases. However, efficient and safe delivery of siRNAs to the central nervous system (CNS) remains a critical challenge.
View Article and Find Full Text PDFJ Pept Sci
October 2025
Institute of Technology, University of Tartu, Tartu, Estonia.
The development of therapeutic small interfering RNAs (siRNAs) has lately gained significant momentum due to their ability to silence genes in a highly specific manner. The main obstacle withholding the wider translation of siRNA-based drug modalities is their limited half-life and poor bioavailability, especially in extra-hepatic tissues. Consequently, various drug delivery systems (DDSs) have been developed to improve the delivery of siRNAs, including short delivery peptides called cell-penetrating peptides (CPPs).
View Article and Find Full Text PDFInt J Biol Macromol
September 2025
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, 400019, India. Electronic address:
Polysaccharide copolymers Conjuates have surfaced as a versatile foundation in the development of advanced smart drug delivery systems, owing to their inherent biocompatibility, biodegradability, and capacity for chemical modification. This review brings into focus the recent advances in co-polymeric drug delivery systems based on naturally occurring polysaccharides like chitosan, alginate, dextran, hyaluronic acid, pullulan, guar gum, xanthan gum, agarose, gellan gum, and starch. Their structural malleability and functionalization capabilities are emphasized to engineer therapeutic payload stability, bioavailability, and controlled release.
View Article and Find Full Text PDFNanomedicine
September 2025
The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China; Department of Nephrology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, Gansu, People's Republic of China; Key laboratory of nephropathy, The S
Diabetic kidney disease (DKD), a prominent microvascular complication of diabetes mellitus and the leading cause of end-stage renal disease (ESRD), was addressed through a novel nanotherapeutic approach. This study engineered folic acid-conjugated poly(lactic-co-glycolic acid) nanoparticles (FA-PLGA NPs) for the folate receptor (FR)-targeted delivery of Toll-like receptor 4 small interfering RNA (TLR4 siRNA) to treat diabetic nephropathy (DN). In a streptozotocin-induced DN murine model, administration of FA-PLGA NPs/TLR4 siRNA significantly mitigated renal injury compared to untreated DN controls.
View Article and Find Full Text PDFAdv Mater
September 2025
State Key Laboratory of Chemical Resource Engineering, Key Lab of Biomedical Materials of Natural Macromolecules (Beijing University of Chemical Technology, Ministry of Education), Beijing Laboratory of Biomedical Materials, Beijing University of Chemical Technology, Beijing, 100029, China.
Excessive inflammation and overexpressed matrix metalloproteinases (MMPs) are significant factors in the prolonged healing of chronic diabetic wounds. Here, a precise gene therapy strategy is proposed utilizing siRNA and employing intelligent responsive materials for controlled release to mechanistically intervene in the pathological process of chronic non-healing wounds. The system employs a cationic hyperbranched aminoglycoside with disulfide bonds (SS-HPT) as its core delivery mechanism.
View Article and Find Full Text PDF